Brokerages Anticipate Intellia Therapeutics Inc (NASDAQ:NTLA) to Announce -$0.53 Earnings Per Share

Equities research analysts expect Intellia Therapeutics Inc (NASDAQ:NTLA) to post earnings per share of ($0.53) for the current quarter, Zacks Investment Research reports. Six analysts have made estimates for Intellia Therapeutics’ earnings. The highest EPS estimate is ($0.47) and the lowest is ($0.64). Intellia Therapeutics posted earnings per share of ($0.43) in the same quarter last year, which suggests a negative year-over-year growth rate of 23.3%. The company is scheduled to issue its next quarterly earnings report on Wednesday, February 26th.

According to Zacks, analysts expect that Intellia Therapeutics will report full year earnings of ($2.09) per share for the current fiscal year, with EPS estimates ranging from ($2.31) to ($1.97). For the next year, analysts anticipate that the company will post earnings of ($2.28) per share, with EPS estimates ranging from ($3.00) to ($1.71). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side analysts that cover Intellia Therapeutics.

Intellia Therapeutics (NASDAQ:NTLA) last released its earnings results on Thursday, October 31st. The company reported ($0.49) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.61) by $0.12. The firm had revenue of $10.60 million for the quarter, compared to analyst estimates of $9.17 million. Intellia Therapeutics had a negative return on equity of 33.00% and a negative net margin of 225.54%. The company’s revenue was up 43.2% on a year-over-year basis. During the same quarter last year, the firm posted ($0.53) EPS.

Several equities research analysts have recently weighed in on the company. Raymond James raised Intellia Therapeutics from a “market perform” rating to an “outperform” rating and set a $24.00 price objective for the company in a research report on Friday, November 1st. Chardan Capital set a $57.50 target price on shares of Intellia Therapeutics and gave the stock a “buy” rating in a research report on Friday, September 27th. BidaskClub upgraded shares of Intellia Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, November 28th. Zacks Investment Research raised shares of Intellia Therapeutics from a “hold” rating to a “strong-buy” rating and set a $15.00 price target for the company in a report on Wednesday, November 6th. Finally, ValuEngine lowered shares of Intellia Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, November 5th. Two analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $25.21.

Shares of NTLA stock traded down $0.13 during trading hours on Friday, reaching $17.10. 606,847 shares of the company’s stock were exchanged, compared to its average volume of 575,467. Intellia Therapeutics has a fifty-two week low of $10.26 and a fifty-two week high of $19.00. The stock has a market capitalization of $835.88 million, a P/E ratio of -8.64 and a beta of 2.84. The business has a fifty day moving average price of $13.84 and a 200-day moving average price of $14.78. The company has a quick ratio of 7.89, a current ratio of 7.89 and a debt-to-equity ratio of 0.05.

Institutional investors have recently bought and sold shares of the business. Benjamin Edwards Inc. lifted its holdings in shares of Intellia Therapeutics by 60.9% during the 2nd quarter. Benjamin Edwards Inc. now owns 1,691 shares of the company’s stock worth $28,000 after acquiring an additional 640 shares during the period. Janney Montgomery Scott LLC raised its position in Intellia Therapeutics by 3.9% in the second quarter. Janney Montgomery Scott LLC now owns 32,185 shares of the company’s stock worth $527,000 after purchasing an additional 1,202 shares in the last quarter. HighTower Advisors LLC raised its position in Intellia Therapeutics by 5.3% in the second quarter. HighTower Advisors LLC now owns 36,437 shares of the company’s stock worth $598,000 after purchasing an additional 1,826 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in Intellia Therapeutics by 23.4% during the second quarter. JPMorgan Chase & Co. now owns 10,000 shares of the company’s stock worth $152,000 after purchasing an additional 1,894 shares during the period. Finally, Bank of Montreal Can lifted its stake in Intellia Therapeutics by 406.5% during the second quarter. Bank of Montreal Can now owns 3,824 shares of the company’s stock worth $63,000 after purchasing an additional 3,069 shares during the period. 89.92% of the stock is owned by hedge funds and other institutional investors.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, and primary hyperoxaluria.

Recommended Story: How Do Tariffs Affect Trade Balances?

Get a free copy of the Zacks research report on Intellia Therapeutics (NTLA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Intellia Therapeutics (NASDAQ:NTLA)

Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.